Japanese conglomerate AGC has offered a takeover bid of €240 million to acquire 100% of Italian biotech company cum contract development and manufacturing organization (CDMO) Molecular Medicine (Molmed), valuing the latter at €0.518 per share. The clinical-stage Italian biotech company is engaged in research, development, manufacturing and also clinical validation of gene and cell therapies. […]
Chinese CDMO WuXi Vaccines has signed a 20-year contract worth around $3bn with an undisclosed vaccine company to use a dedicated vaccine manufacturing facility in Ireland to supply commercial vaccine products manufactured from it for the global market. WuXi Vaccines, which is a joint venture between WuXi Biologics and Shanghai Hile Bio-technology, had announced an […]
Drug manufacturer Catalent Pharma Solutions has wrapped up its previously announced $315 million acquisition of MaSTherCell Global, a technology-focused cell and gene therapy contract development and manufacturing organization (cell and gene therapy CDMO). The acquisition, which was announced earlier this month, is said to position Catalent as a major technology, development, and manufacturing partner for […]
Recipharm acquisition of Consort Medical : Swedish pharma group Recipharm has agreed to acquire Consort Medical, a British contract development and manufacturing organization (CDMO) for £505 million, as per the latest pharma acquisition news. The transaction is said to help Recipharm become a major inhalation company and places it among the top five CDMO players […]